Work

Results of a phase II trial of docetaxel (DOC), bevacizumab (BEV), and androgen deprivation therapy (ADT) for biochemical relapse (BCR) after definitive local therapy for prostate cancer (PC).

Year: 2014

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2014.32.4_suppl.54

Authors: Rana R. McKay, Kathryn P. Gray, Julia H. Hayes, Glenn J. Bubley, Jonathan E. Rosenberg, Philip W. Kantoff, Mary-Ellen Taplin

Institutions: Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, Memorial Sloan Kettering Cancer Center

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2590932941

Cites:

Cited by: 1

Related to: 10